The prevalence and impact of psychiatric comorbidities on hospitalized inflammatory bowel disease patients in the United States: insights from the National Inpatient Sample from 2009-2018

Background Patients with inflammatory bowel disease (IBD) are at increased risk of anxiety and mood disorders.This study examines the temporal trends and clinical impact of anxiety and mood disorder diagnoses in hospitalized IBD patients in the United States during a 10-year period. MethodsUsing the National Inpatient Sample from 2009-2018, all IBD-related discharges in adults were analyzed.Primary outcomes were the prevalence and temporal trends of mood disorder and anxiety diagnoses for IBD-related admissions.The impact of the psychiatric comorbidities on clinical outcomes was also evaluated.Results A total of 1,718,736 IBD-related discharged were identified.A diagnosis of anxiety or a mood disorder was found to have a prevalence of 16.44% and 18.97%, respectively, amongst IBDrelated admissions.The prevalence of anxiety disorders amongst hospitalized IBD patients increased significantly (from 12.13% to 20.26%), whereas the prevalence of mood disorders did not (17.46%and 18.9%).IBD admissions with psychiatric comorbidities had lower rates of IBD-related complications or mortality during hospitalization compared to IBD admissions without comorbid psychiatric diagnoses.This population, however, was more likely to experience certain comorbidities such as Clostridioides difficile, pneumonia, and venous thromboembolism, as well as a longer hospitalization. ConclusionsThe prevalence of comorbid anxiety among hospitalized IBD patients in the United States matches or exceeds the prevalence of anxiety in the general hospitalized population.Given its association with more in-hospital complications and a longer hospital stay, it is important to further understand how psychological screening and mental health services can improve the management of hospitalized IBD patients.